TY - JOUR
T1 - Sex, digitalis, and the sodium pump.
AU - Blaustein, Mordecai P.
AU - Robinson, Shawn W.
AU - Gottlieb, Stephen S.
AU - Balke, C. William
AU - Hamlyn, John M.
PY - 2003/3
Y1 - 2003/3
N2 - Foxglove and its constituents therapeutic agent digitalis have been used for centuries for the treatment of heart failure. All digitalis-like cardiotonic steroids enhance heart contraction through a mechanism involving the inhibition of the Na(+),K(+)- ATPase. Recently, Rathore and colleagues reported that sex-based differences may exist in the efficacy of digoxin for the treatment of heart failure. The authors of the study found that female patients exhibited increased risk of death associated with digoxin therapy, whereas male patients appeared to have no increased risk of death related to digoxin therapy. Blaustein and colleagues delve into the report and discuss possible explanations for these findings, suggest alternative ones, and advocate for enrolling greater numbers of women in clinical studies.
AB - Foxglove and its constituents therapeutic agent digitalis have been used for centuries for the treatment of heart failure. All digitalis-like cardiotonic steroids enhance heart contraction through a mechanism involving the inhibition of the Na(+),K(+)- ATPase. Recently, Rathore and colleagues reported that sex-based differences may exist in the efficacy of digoxin for the treatment of heart failure. The authors of the study found that female patients exhibited increased risk of death associated with digoxin therapy, whereas male patients appeared to have no increased risk of death related to digoxin therapy. Blaustein and colleagues delve into the report and discuss possible explanations for these findings, suggest alternative ones, and advocate for enrolling greater numbers of women in clinical studies.
UR - http://www.scopus.com/inward/record.url?scp=1542326304&partnerID=8YFLogxK
U2 - 10.1124/mi.3.2.68
DO - 10.1124/mi.3.2.68
M3 - Review article
C2 - 14993426
AN - SCOPUS:1542326304
SN - 1534-0384
VL - 3
SP - 68-72, 50
JO - Molecular interventions
JF - Molecular interventions
IS - 2
ER -